INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
Subscribe
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
SEARCH
SEARCH
advanced search
EXPERT VIEW
EXPERT VIEW
FROM FRAGMENTED PROCUREMENT TO INTEGRATED ASSEMBLY: HOW THE INJECTABLE DEVICE INDUSTRY IS RETHINKING EQUIPMENT STRATEGY
Jordan Xu examines the shift from fragmented procurement to integrated, turnkey assembly solutions, exploring the deep technical and regulatory drivers behind this evolution as the industry increasingly recognises that the real differentiator is not the speed of individual machines but the seamless integration of the entire assembly process.
EXPERT VIEW
CANNULA SELECTION FOR PREFILLED SYRINGE APPLICATIONS
Dr Wenzel Novak and Stephan Schatz discuss the considerations that go into optimising cannula selection for an injection device, including patient comfort, drug requirements, manufacturability and intended use case, arguing that the best selection will be one that successfully balances these factors rather than maximising a single parameter.
EXPERT VIEW
Dr Alex Vasiev
GETTING OUT OF A JAM: SUSPENSION DELIVERY, OCCLUSION AND DEVICE DESIGN
Dr Alex Vasiev discusses suspension-based parenteral systems, including micro- and nanoparticle suspensions and colloidal dispersions, where sedimentation, mechanical bridging and interfacial forces can strongly influence delivery performance.
EXPERT VIEW
Tim Quigg
PLATFORMS IN BIOPHARMA DEVICE DEVELOPMENT: FROM PRACTICE TO STRATEGY
Tim Quigg, Katie Ogden with Dr Shirish Ingawale discuss some of the key points from the 2026 PFS & Injectable Drug Devices East Coast Conference regarding biopharma platform technology.
EXPERT VIEW
Dr Sahab Babaee
ENABLING DELIVERY OF LYOPHILISED BIOLOGICS VIA SIMULATION-LED DEVELOPMENT OF DUAL-CHAMBER SYSTEMS
Dr Sahab Babaee and Dr Matthew Hancock discuss the potential of using modelling and simulation when designing dual-chamber injection devices, which can enable device designers to investigate the complex interactions that take place within a dual-chamber system without a physical prototype and discover potential failure modes much earlier in the design process.
EXPERT VIEW
Jack Dunkley
RECONSTITUTION TO CO-DELIVERY: DESIGNING MULTICHAMBER DEVICES FOR BETTER PATIENT EXPERIENCES
Jack Dunkley delves into the architectural principles of multichamber systems for injectable formulations and considers how to overcome the design challenges involved.
EXPERT VIEW
Andy Wertheim
INDUSTRIAL ARCHITECTURE: THE NEXT COMPETITIVE ADVANTAGE IN WEARABLE INJECTORS
Andy Wertheim puts forward the case that wearable drug delivery devices comprise two separate architectures – therapeutic and industrial – that must be developed and implemented in tandem if a development programme is to achieve long-term commercial success.
EXPERT VIEW
Dr Matthew Roberts
DESIGN VERIFICATION FOR THE REAL WORLD: COMPLEX DRUG DELIVERY IN UNCONTROLLED ENVIRONMENTS
Dr Matthew Roberts and Andrew Fiorini explore the key steps involved in building a successful design verification programme for ambulatory electromechanical infusion systems and share the lessons they have learned along the way.
EXPERT VIEW
Dr Sammy Hassan
Designing a Wearable Drug Delivery Pump
Dr Sammy Hassan delves into the measures required to ensure safe and reliable use of wearable drug delivery pumps, explaining the difficulties and benefits of incorporating such standards into a device.
EXPERT VIEW
John Ward
THE HIDDEN RISKS IN DRUG-DEVICE DELIVERY: WHY THE FINAL STAGE DEFINES LAUNCH SUCCESS
John Ward and Paul Hamill explore the structural and operational risks embedded in late-stage drug-device delivery, why these risks are intensifying and how the industry is beginning to rethink its approach to downstream execution.
EXPERT VIEW
Chris Hurlstone
INDUSTRIALISING DRUG DELIVERY DEVICES: INSIGHTS FROM 40 YEARS OF GETTING TO MARKET
Chris Hurlstone looks at the process of developing drug delivery systems through the industrialisation phase and explores ways to address the challenges that arise along the way. Drawing on Team’s 40-year track record of supporting drug delivery device innovation, the insights are intended for teams involved in developing drug delivery systems, particularly those responsible for design, engineering, industrialisation and manufacturing transfer.
EXPERT VIEW
Jon Powell
DE-RISKING POST-MARKET CHANGE THROUGH PILOT PRODUCTION
Jon Powell explores how pilot production, delivered through integrated design, development and manufacturing capabilities, can be used to de-risk change in commercial-scale drug delivery devices, highlighting how such approaches can improve confidence in decision-making while reducing overall time and cost.
EXPERT VIEW
Stephan Vogel
EFFICIENCY, DATA INTEGRITY AND QUALITY ASSURANCE IN THE PRODUCTION OF INSULIN PENS
Stephan Vogel discusses the role of advanced monitoring technologies in high-volume medical device manufacturing, considering the key role they play in ensuring quality and compliance with regulatory requirements and how analysing data centrally can support consistency across lines and sites.
EXPERT VIEW
Dr Sahab Babaee
ORAL DELIVERY OF MACROMOLECULES: CHALLENGES AND OPPORTUNITIES FOR DEVICE-ENABLED GI DELIVERY
Dr Sahab Babaee discusses the potential of device-based approaches to enable the delivery of macromolecules via the gastrointestinal tract, considering the constraints and possibilities of mucosal delivery devices, as well as the technologies currently being investigated to make this potential a reality.
EXPERT VIEW
Leo Pan
TRANSDERMAL DRUG DELIVERY: ENHANCING PERMEABILITY AND IN VIVO TRANSLATION
Dr Leo Pan provides insights into the field of transdermal drug delivery and investigates the two primary approaches being taken to advance the sector – enhancing the ability of drugs to permeate through the skin barrier and translating in vitro data to an in vivo reality.
EXPERT VIEW
Dr Mehul Desai
ANTIBODY-DRUG CONJUGATES: AN EMERGING FRONTIER IN IV TO SC CONVERSION
Dr Mehul Desai, Dr Michael Hageman and Dr Wei Chen examine the growing antibody-drug conjugate market, the unique formulation challenges these therapies present for subcutaneous delivery and how innovations in on-body injector technology may offer a practical path forwards.
EXPERT VIEW
Norbert Kübler
STERILE DRUG PRODUCTION: AN EVER-EVOLVING MARKET
Dr Norbert Kübler discusses the current state of sterile drug products, considering how advancing technology is changing the field, the role of quality control and the challenges faced during scale-up and manufacturing.
EXPERT VIEW
Henryk Badack
MAINTAINING RELIABLE DRUG DELIVERY THROUGH SUSTAINABLE OPERATIONS
Henryk Badack considers how a holistic approach to sustainability can enable CDMOs to implement efficient operations strategically – while introducing initiatives that address environmental, economic and social elements.
EXPERT VIEW
Kiara Taylor
LATE-STAGE MATERIAL SUBSTITUTION: AMBITION FOR SUSTAINABILITY OR TRANSFER-TIME RISK?
Kiara Taylor delves into the challenges of changing materials to enhance sustainability after a design has been transferred to manufacturing, considering the reasons that might drive such a change, the issues involved and the benefits that can be gained.
EXPERT VIEW
Adam Tilley
SUSTAINABILITY IN DRUG DELIVERY
Adam Tilley and David Cook explore how carbon footprint considerations can be integrated into the drug delivery device design lifecycle, highlighting key sustainability decisions faced by design engineers and emerging tools that support those evaluations.
EXPERT VIEW
Greg Anderson
CHALLENGES & OPPORTUNITIES TO OPTIMISE SUSTAINABILITY IN PHARMACEUTICAL PACKAGING & COMBINATION DEVICES
Greg Anderson discusses the need to improve the sustainability and circularity of pharmaceutical packaging and drug delivery devices, looking at the challenges and providing a clear outline of the potential opportunities for improvement.
EXPERT VIEW
Markus Laubscher
ENABLING A SUSTAINABLE FUTURE FOR pMDIs WITH LOW-GWP MEDICAL PROPELLANTS
Markus Laubscher discusses the role of pressurised metered dose inhalers in the context of healthcare’s drive towards sustainability, considering the need for lower-global-warming-potential propellants and why it is important to preserve these inhalers as a key aspect of respiratory care.
EXPERT VIEW
Dr Matthew Owen
INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES
Dr Matthew Owen reviews the formulation and device challenges, designs and considerations that are shaping the nasal delivery market.
EXPERT VIEW
Gregg Draudt
INTRAVITREAL INJECTIONS – WHAT IS CAUSING PATIENTS TO DISCONTINUE THERAPY AND WHY IS IT SO HARD TO FIX?
Gregg Draudt considers the significant issue of treatment discontinuation in intravitreal therapies, digging into the root causes of poor adherence and what will be required to reverse this trend in a way that caters to the full range of stakeholders, who often have contradictory requirements.
EXPERT VIEW
Tina Rogers
WuXi AppTec
ADDRESSING OCULAR SAFETY CHALLENGES IN ADC DEVELOPMENT
Dr Tina Rogers discusses antibody-drug conjugates and their potential in direct targeting and treatment of cancers, going further to assess the risks of these treatments and how they can be mitigated.
EXPERT VIEW
Tom Oakley
TRENDS FOR 2026
A new reality is forming as we enter 2026 – it will not be “business as usual”. Geopolitical forces in the largest market for pharmaceuticals, the US, are likely to mean substantial changes. Here, Tom Oakley and Alex Vasiev cover those changes, the incretin juggernaut and the march of technical progress with “minitablet” dispensers, large-volume injectors and dual-chamber devices.
1
2
3
…
15
Next
Top
